MATRIXX Software Teams Up with Hewlett Packard Enterprise to Deliver Real-time 'Monetization-as-a-Service' to CSPs
24.11.2020 14:00:00 EET | Business Wire | Press release
MATRIXX Software, the global leader in 5G monetization solutions, has collaborated with Hewlett Packard Enterprise (HPE) to bring MATRIXX Digital Commerce to Communications Service Providers (CSPs) via HPE GreenLake, an elastic-as-a-service platform that can run on-premises, at the edge or in a colocation.
MATRIXX Digital Commerce provides a cloud native, real-time converged charging and commerce platform that enables CSPs to compete at web scale. Unique in its offering, MATRIXX makes it possible for CSPs to move quickly, engage digitally and operate more efficiently. Industry-leading service providers such as Dish, Swisscom, Orange, and Three have chosen MATRIXX as their future proof monetization solution as they evolve to cloud native architectures and develop new 5G business models for B2C, B2B and B2B2X.
The demand for and consumption of high speed, high quality network resources and value-added services has skyrocketed this year and will continue to do so as CSPs invest in 5G rollouts. To accelerate the delivery of new services, CSPs are increasingly turning to the cloud to provide the operational agility required to support rapid and continuous development and deployment of new services and offerings. By leveraging HPE GreenLake, service providers benefit from combining the agility and economics of public cloud with the security and performance of on-premises infrastructure required by a mission critical, high volume, low latency application such as MATRIXX Digital Commerce.
“We are excited to be collaborating with MATRIXX Software to deliver their innovative charging and commerce platform,” said Claus Pedersen, VP and GM, Worldwide Telco Infrastructure at HPE. “Delivering MATRIXX as-a-service is another proof point of HPE’s ability to deliver business advantage to CSPs whilst freeing them from the Capex investments and the daily cost and complexity of managing these applications on-premises. We deliver these advantages on HPE’s proven carrier-grade infrastructure whilst enabling our customers to flexibly scale the capacity to their business needs.”
“We are thrilled to be collaborating with HPE to bring disruptive propositions to the highly competitive CSP market,” said Marc Price, CTO, MATRIXX Software, “Together, MATRIXX and HPE deliver state-of-the-art solutions that enable CSPs to focus on commercial and technology innovations so they can quickly capture the imagination of their customers and increase market share.”
HPE GreenLake Cloud Services provide customers with a powerful foundation to drive digital transformation through an elastic-as-a-service platform that can run on-premises, at the edge, or in a colocation facility. HPE GreenLake combines the simplicity and agility of the cloud with the governance, compliance, and visibility that comes with hybrid IT. HPE GreenLake offers a range of cloud services that accelerate innovation, including cloud services for compute, container management, data protection, HPC, machine learning operations, networking, SAP HANA, and storage, VDI, and VMs. The HPE GreenLake Cloud Services business is rapidly growing with over $4 billion USD in total contract value, over 700 partners selling HPE GreenLake, and more than 1000 customers in all industry sectors and sizes including Fortune 500 companies.
About MATRIXX Software
MATRIXX Software is the global leader in 5G monetization for the communications industry. Serving many of the world’s largest operator groups, regional carriers, and emerging digital service providers, MATRIXX delivers a cloud native digital commerce solution that enables unmatched commercial and operational agility. Unifying IT & networks, MATRIXX delivers a network-grade converged charging system (CCS) enabling efficient hyper-scaling of infrastructure to support consumer services, wholesale and enterprise marketplaces. Through its relentless commitment to product excellence and customer success, MATRIXX empowers businesses to harness network assets and business agility to succeed at web scale.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201124005101/en/
Contact information
Jennifer Kyriakakis
mediainquiry@matrixx.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
CorFlow Therapeutics Announces Successful Completion of Phase 1 and First Patients Enrolled in Phase 2 of the MOCA II Pivotal Trial, Approval to Start the REVITALISE RCT in Europe, and Strengthening of Clinical Leadership30.4.2026 14:00:00 EEST | Press release
CorFlow Therapeutics AG (CorFlow), a clinical-stage company focused on transforming the diagnosis and treatment for heart attack patients, today announced multiple milestones in advancing its clinical program and the strengthening of clinical leadership. Phase 1 of the company’s MOCA II FDA Pivotal Trial was successfully reached after safety and performance goals were met with STEMI heart attack patients who had the proprietary PCoFI diagnostic measurement of microvascular obstruction (MVO) made during a stenting procedure, when compared to the reference standard diagnosis by cardiac MRI in the subsequent days. Phase 1 included 19 patients enrolled across 5 US and 3 European sites. MOCA II follows the FIH MOCA I study and primarily aims to validate the threshold value of the proprietary PCoFI measurement for diagnosing MVO in the setting of primary angioplasty compared to cardiac MRI. This milestone achievement, which was confirmed by the study’s independent DSMB (Data and Safety Monit
Agendia to Present New Data Demonstrating the Expanded Clinical Utility of MammaPrint ® and BluePrint ® at the 2026 ESMO Breast Cancer Annual Congress30.4.2026 14:00:00 EEST | Press release
Agendia®, Inc., a leader in precision oncology for breast cancer, today announced it will present new data at the 2026 European Society for Medical Oncology (ESMO) Annual Congress on Breast Cancer, taking place May 6-8 in Berlin, Germany. The company will present two posters featuring data from the prospective FLEX Study and an independent post hoc analysis of the landmark MINDACT trial that underscore the prognostic value of MammaPrint® + BluePrint® in early-stage breast cancer (EBC). Poster #65P | Thursday, May 7, 13:15 – 14:15 p.m. CEST | Presenter: Elena Shagisultanova Prognostic Performance of MammaPrint in Patients with Small T1a, b, and c Node-Negative Early Breast Cancer A retrospective analysis from the FLEX Study involving 4,349 patients highlights the biological heterogeneity within small, node-negative (T1a, b, and c) tumors – a group that typically has favorable outcomes. MammaPrint (MP) identified a High Risk 2 (H2) subset, representing 10% of all patients and 5% of those
The Biggest Predictor of Business Growth Is Behavior30.4.2026 10:00:00 EEST | Press release
IDEO, the global design and innovation company, today announced the IDEO Innovation Quotient (IDEO IQ), a new report measuring how workplace behaviors drive business performance across 100 of the world’s largest companies. Those with the highest IDEO IQ scores earned nearly $20 billion in profit last year—50% higher than average and three times more than those ranked at the bottom. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260429978890/en/ The IDEO Innovation Quotient (IDEO IQ) is a new report measuring how workplace behaviors drive business performance across 100 of the world’s largest companies. The IDEO IQ surveyed 266 leaders in product and innovation roles at 100 of the world’s largest companies across the Media & Technology, Healthcare, and Consumer Goods sectors. The report is the first of its kind to draw a direct line between how companies operate internally and their financial performance. Companies were surve
Suzano Sells 12.7 Million Tonnes of Pulp for the First Time in Its History30.4.2026 01:22:00 EEST | Press release
Suzano(B3: SUZB3 | NYSE: SUZ), the world’s largest pulp producer, announces its results for the first quarter of 2026 (1Q26), achieving a new all‑time record in pulp sales. Over the 12‑month period from April 2025 to March 2026, the company sold 12.7 million tonnes of pulp, the highest volume ever recorded in its history. During the same period, Suzano also sold 1.7 million tonnes of paper across the packaging, printing and writing, specialty, and tissue segments. This unprecedented sales level mainly reflects the increase in production capacity following the start‑up of the Ribas do Rio Pardo pulp mill in the state of Mato Grosso do Sul, as well as Suzano’s strong operational efficiency across its production lines and supply chains, serving customers in more than 100 countries worldwide. In the first quarter of 2026, Suzano sold a total of 3.2 million tonnes, comprising 2.8 million tonnes of pulp and 378 thousand tonnes of paper. Net revenue amounted to BRL 11.0 billion, while adjuste
The Estée Lauder Companies Announces Minority Investment in Luxury Clinical Skin Care Brand 111SKIN29.4.2026 23:30:00 EEST | Press release
The Estée Lauder Companies Inc. (NYSE:EL) today announced a minority investment in 111SKIN, a luxury clinical skin care brand founded by renowned plastic and reconstructive surgeon Dr. Yannis Alexandrides. Terms of the investment were not disclosed. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260429495879/en/ 111SKIN's Reparative Collection Founded in 2012, 111SKIN was originally developed by Dr. Alexandrides to accelerate his patients’ healing time following procedures. At the heart of the brand is its innovative NAC Y2™, a pioneering complex designed to support skin repair and maintain a healthy, radiant and resilient complexion. Building on the foundation of this clinical expertise, 111SKIN has developed a portfolio of more than 30 products, anchored by its Black Diamond and Reparative collections and priced from $50 to $1,000. “Skin care is entering a new phase, shaped by the convergence of procedures, longevity and b
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom